Janux Therapeutics announced that it has commenced an underwritten public offering of $175M of shares of its common stock. BofA Securities, TD Cowen, Cantor Fitzgerald & Co. and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering. The company intends to use the net proceeds from the offering to advance clinical development of its internal product pipeline and for general corporate purposes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JANX:
